Literature DB >> 15839622

Reduced alcohol use in the staining of Pap smears: a satisfactory low-cost protocol for cervical cancer screening.

Titilola O Akinremi1, Saloney Nazeer, Martin Tötsch.   

Abstract

OBJECTIVE: To describe a low-cost Papanicolaou staining procedure that can be applied to conventional and monolayer gynecologic preparations. STUDY
DESIGN: The amount of alcohol consumed in the procedure, which normally accounts for > 80% of the cost of processing, was reduced drastically by (1) using only 1 modified cytoplasmic counterstain (EA type), thereby (2) reducing the number of alcohol rinses by over half Orange-G dye is omitted.
RESULTS: The resultant effect of the modified staining protocol is quite satisfactory and attractive to screening eyes: nuclear details are sharp and crisp, while the cytoplasm contains transparent differential staining with blue-green and pink.
CONCLUSION: A reduction in the cost of staining should encourage cervical cancer screening, especially in developing countries, where cost is a limiting factor, thus making it possible for more women to be screened without increasing the cost of the program.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15839622     DOI: 10.1159/000326127

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  3 in total

1.  Perception and utilization of cervical cancer screening services among female nurses in University College Hospital, Ibadan, Nigeria.

Authors:  Oyedunni Sola Arulogun; Opemipo Olubunmi Maxwell
Journal:  Pan Afr Med J       Date:  2012-04-15

Review 2.  Cervical cancer prevention and treatment research in Africa: a systematic review from a public health perspective.

Authors:  Sarah Finocchario-Kessler; Catherine Wexler; May Maloba; Natabhona Mabachi; Florence Ndikum-Moffor; Elizabeth Bukusi
Journal:  BMC Womens Health       Date:  2016-06-04       Impact factor: 2.809

3.  Drivers of cervical cancer screening uptake in Ibadan, Nigeria.

Authors:  Oluwatosin E Ilevbare; A A Adegoke; C M Adelowo
Journal:  Heliyon       Date:  2020-03-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.